Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

06/04/2026

The evidence for single-session PML continues to grow.

Interim data from the first 50 patients in the RAPID-PE Study - a prospective, multicenter U.S. study evaluating on-the-table (OTT) pharmaco-mechanical lysis (PML) - was presented at TCT 2025. The analysis demonstrated that on-the-table PML using the BASHIR® Endovascular Device can be performed efficiently and without post-procedure infusion, offering the interventional community meaningful insight into what structured, targeted PE intervention looks like in practice.

As the study continues to enroll, the RAPID-PE Study reinforces the clinical case for single-session care in acute PE treatment.

Learn more at Thrombolex.com.

06/02/2026

The results of the RESCUE-II Study have been published in JACC: Advances, and the data speaks for itself.

This peer-reviewed publication validates the role of the BASHIR® Endovascular Device as a clinically proven solution in the treatment of A&VTE, demonstrating significant reductions in RV/LV ratio and PA obstruction with no major bleeding events and no requirement for post-procedure infusion. All achieved in a single, on-the-table (OTT) pharmaco-mechanical lysis (PML) session.

In PE care, clinical confidence is earned through evidence. The RESCUE-II Study delivers exactly that.

Read the full publication in JACC: Advances at Thrombolex.com.

05/31/2026

Clinical confidence is built on evidence, and the RESCUE-II Study delivers.

In the RESCUE-II Study, patients treated with the BASHIR® Endovascular Device for acute pulmonary embolism demonstrated significant reductions in RV/LV ratio and PA obstruction, with no major bleeding events and no requirement for post-procedure infusion - all in a single session.

Learn more here: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101789

Thrombolex.com

05/29/2026

When treating pulmonary embolism, focus matters at every step.

The BASHIR® Endovascular Device is designed to support targeted thrombolytic delivery and mechanical clot fragmentation, helping clinicians maintain procedural consistency and clinical confidence throughout a single, on-the-table (OTT) pharmaco-mechanical lysis (PML) session.

Thrombolex.com

05/27/2026

Evidence-based medicine is not a preference in pulmonary embolism treatment. It is a responsibility. Every clinical choice - the approach, the therapy, the protocol - shapes what happens next for the patient.

Choosing a therapy that is safe, reliable, and supported by clinical data matters because the outcomes on the other side of that decision belong to a real person. That's why Thrombolex invests in the clinical programs, resources, and a Family of Endovascular Devices that give the interventional community the evidence and tools they need to deliver better outcomes for every patient.

Thrombolex.com

05/25/2026

On Memorial Day, we pause to honor the brave men and women who gave their lives in service to our country. Their sacrifice inspires what we do - advancing care that helps save lives every day.

Thrombolex.com

05/21/2026

Clinical confidence should be accessible, not contingent on infrastructure.

The BASHIR® Endovascular Device is a standalone technology that requires no capital equipment, making it straightforward to integrate into existing lab workflows across a broad range of healthcare facilities. In environments where transferring pulmonary embolism patients between facilities is challenging, having a targeted, reliable pharmaco-mechanical lysis (PML) solution available on-site can make a meaningful difference in how quickly and consistently care is delivered.

Thrombolex.com

05/18/2026

The Thrombolex Clinical Library offers physician-focused case materials, procedural videos, and clinical perspectives designed to support practical understanding of Pharmaco-Mechanical Lysis (PML) in practice.

Whether you are exploring the BASHIR® Endovascular Device for the first time or deepening your procedural knowledge, these resources are built to support informed decision-making at every stage.

Explore the Clinical Library at Thrombolex.com.

05/15/2026

In the RESCUE-II clinical trial using on-the-table (OTT) pharmaco-mechanical lysis (PML), the BASHIR® Endovascular Device was used to treat intermediate-risk PE, the median procedure time was approximately 39 minutes, and the median length of stay was 2.8 days. No major bleeding events were observed in the reported cohort.

Efficiency in PE intervention is not about speed alone. It is about structure, consistency, and a coordinated approach that supports precise thrombolytic delivery and mechanical clot fragmentation from start to finish.

That is what doing more with less looks like in practice.

Read more here: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101789

Thrombolex.com

05/12/2026

Earlier this year, Thrombolex closed a $50 million Series A financing led by OrbiMed - a milestone that strengthens our ability to expand access to pharmaco-mechanical lysis (PML) and continue generating the clinical evidence that matters most to the interventional community.

For clinicians treating pulmonary embolism and venous thrombus, this investment means broader commercial reach, continued development of the BASHIR® Endovascular Device platform, and a sustained commitment to making single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) a standard of care.

Learn more at Thrombolex.com.

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?